Tonix Pharmaceuticals Holding Investor Presentation — February 2018 - Tonix Pharmaceuticals Holding Corp.

Document content

Version P0099 2-8-18 (Doc 0321)

Investor Presentation

Cautionary Note on Forward -Looking Statements

Certain statements in this presentation regarding strategic plans, expectations and objectives for future

operations or results are “forward -looking statements” as defined by the Private Securities Litigation Reform

Act of 1995. These statements may be identified by the use of forward -looking words such as “anticipate,”

“believe,” “forecast,” “estimate” and “intend,” among others . These forward -looking statements are based on

Tonix’s current expectations and actual results could differ materially . There are a number of factors that

could cause actual events to differ materially from those indicated by such forward -looking statements . These

factors include, but are not limited to, substantial competition ; our need for additional financing ; uncertainties

of patent protection and litigation ; uncertainties of government or third party payor reimbursement ; limited

research and development efforts and dependence upon third parties ; and risks related to failure to obtain

U.S. Food and Drug Administration clearances or approvals and noncompliance with its regulations . As with

any pharmaceutical under development, there are significant risks in the development, regulatory approval

and commercialization of new products . The forward -looking statements in this presentation are made as of

the date of this presentation, even if subsequently made available by Tonix on its website or otherwise . Tonix

does not undertake an obligation to update or revise any forward -looking statement, except as required by

law. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended

December 31, 2016, as filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2017, and

periodic reports filed with the SEC on or after the date thereof . All of Tonix's forward -looking statements are

expressly qualified by all such risk factors and other cautionary statements .

Tonmya®1 (cyclobenzaprine HCl sublingual tablets) bedtime treatment for posttraumatric stress

•Phase 3 HONOR study in military -related PTSD enrolling

•Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA)